Department of Gynaecological Oncology Publications
Publications 2024
-
Highlights from the 25th European Congress on Gynaecological Oncology in Barcelona: the ENYGO-IJGC Fellow Interviews
Int J Gynecol Cancer, 34 (10), 1522-1528
DOI 10.1136/ijgc-2024-005704, PubMed 39181697 -
Digital goal management training for cognitive impairment in cervical cancer survivors-a randomized comparison study
J Cancer Surviv (in press)
DOI 10.1007/s11764-024-01701-4, PubMed 39576570 -
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
Mol Oncol (in press)
DOI 10.1002/1878-0261.13726, PubMed 39245677 -
A cost-effectiveness analysis of sentinel lymph node biopsy compared with lymphadenectomy in intermediate- and high-risk endometrial carcinoma
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2024-005906, PubMed 39433423 -
Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80]
Gynecol Oncol, 183, 7-8
DOI 10.1016/j.ygyno.2024.02.026, PubMed 38484693 -
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
J Immunother Cancer, 12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812 -
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
Gynecol Oncol, 189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895 -
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Int J Gynecol Cancer, 34 (10), 1485-1492
DOI 10.1136/ijgc-2024-005746, PubMed 39074932 -
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03821-9, PubMed 38733380 -
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
Int J Gynecol Pathol, 44 (1), 56-66
DOI 10.1097/PGP.0000000000001030, PubMed 38847524 -
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03912-7, PubMed 39235515 -
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Int J Gynecol Cancer, 34 (12), 1914-1923
DOI 10.1136/ijgc-2024-005663, PubMed 39322609 -
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
J Clin Oncol, JCO2400440 (in press)
DOI 10.1200/JCO.24.00440, PubMed 39353164 -
Surgery for gynecological cancers in the era of personalized medicine: a novel paradigm
Int J Gynecol Cancer, 34 (3), 351
DOI 10.1136/ijgc-2024-005299, PubMed 38438173 -
European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management
Int J Gynecol Cancer, 34 (4), 480-489
DOI 10.1136/ijgc-2024-005293, PubMed 38395448 -
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
Gynecol Oncol, 192, 80-88 (in press)
DOI 10.1016/j.ygyno.2024.11.005, PubMed 39549540 -
Frequency of ERBB2-Low Expression in Endometrial Cancer
JAMA Oncol, 10 (11), 1587-1588
DOI 10.1001/jamaoncol.2024.3660, PubMed 39235791 -
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
J Gynecol Oncol, 35 (6), e117
DOI 10.3802/jgo.2024.35.e117, PubMed 39453395 -
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Ann Oncol, 35 (3), 248-266
DOI 10.1016/j.annonc.2023.11.015, PubMed 38307807 -
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
Eur J Cancer, 200, 113584
DOI 10.1016/j.ejca.2024.113584, PubMed 38330767 -
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet, 404 (10460), 1321-1332
DOI 10.1016/S0140-6736(24)01808-7, PubMed 39288779 -
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lancet, 403 (10434), 1341-1350
DOI 10.1016/S0140-6736(24)00317-9, PubMed 38521086 -
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Cancers (Basel), 16 (11)
DOI 10.3390/cancers16112084, PubMed 38893205 -
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
Gynecol Oncol, 192, 128-136 (in press)
DOI 10.1016/j.ygyno.2024.12.003, PubMed 39657575 -
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
Gynecol Oncol, 188, 103-110
DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691 -
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE
Lancet Oncol, 25 (11), e602-e610
DOI 10.1016/S1470-2045(24)00262-6, PubMed 39216500 -
Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) project
Int J Gynecol Cancer, 34 (11), 1685-1690
DOI 10.1136/ijgc-2024-005697, PubMed 39395820 -
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023 -
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
N Engl J Med, 390 (9), 819-829
DOI 10.1056/NEJMoa2308900, PubMed 38416430 -
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911 -
2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both
Int J Gynecol Cancer, 34 (10), 1580-1587
DOI 10.1136/ijgc-2024-005567, PubMed 39074930 -
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium
Gynecol Oncol, 190, 236-242
DOI 10.1016/j.ygyno.2024.08.019, PubMed 39243699 -
Differential levels of circulating RNAs prior to endometrial cancer diagnosis
Int J Cancer, 155 (5), 946-956
DOI 10.1002/ijc.34951, PubMed 38733362 -
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
Int J Gynecol Cancer, 34 (11), 1677-1684
DOI 10.1136/ijgc-2024-005982, PubMed 39496422 -
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173 -
Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches
Front Oncol, 14, 1389066
DOI 10.3389/fonc.2024.1389066, PubMed 38983926 -
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731 -
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Ann Oncol, 35 (11), 968-980
DOI 10.1016/j.annonc.2024.08.2242, PubMed 39284383
Publications 2023
-
FIGO staging of endometrial cancer: 2023
Int J Gynaecol Obstet, 162 (2), 383-394
DOI 10.1002/ijgo.14923, PubMed 37337978 -
FIGO staging of endometrial cancer: 2023
J Gynecol Oncol, 34 (5), e85
DOI 10.3802/jgo.2023.34.e85, PubMed 37593813 -
Social media ambassadors and collaboration with OncoAlert: a European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022
Int J Gynecol Cancer, 33 (6), 964-970
DOI 10.1136/ijgc-2023-004371, PubMed 37130625 -
Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire
Int J Gynecol Cancer, 33 (2), 231-235
DOI 10.1136/ijgc-2022-003979, PubMed 36600491 -
Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study
Gynecol Oncol, 175, 72-80
DOI 10.1016/j.ygyno.2023.05.070, PubMed 37327542 -
Response: FIGO staging of endometrial cancer 2023
Int J Gynaecol Obstet, 164 (1), 369-372
DOI 10.1002/ijgo.15277, PubMed 38055215 -
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Eur J Cancer, 191, 112966
DOI 10.1016/j.ejca.2023.112966, PubMed 37542936 -
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
Virchows Arch, 484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640 -
Cancer Stem Cell Markers Are Differentially Expressed in Malignant Ovarian Germ Cell Tumors
Int J Gynecol Pathol, 42 (6), 613-619
DOI 10.1097/PGP.0000000000000947, PubMed 37186896 -
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
Clin Exp Metastasis, 41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113 -
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
Gynecol Oncol, 176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615 -
Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway
Int J Cancer, 153 (5), 969-978
DOI 10.1002/ijc.34576, PubMed 37226635 -
Surgery for Recurrent Epithelial Ovarian Cancer
Curr Oncol Rep, 26 (1), 46-54
DOI 10.1007/s11912-023-01480-8, PubMed 38091202 -
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clin Cancer Res, 29 (20), 4068-4075
DOI 10.1158/1078-0432.CCR-23-0621, PubMed 37581616 -
European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors
Int J Gynecol Cancer, 33 (10), 1621-1626
DOI 10.1136/ijgc-2023-004599, PubMed 37783481 -
Is it possible to block cancer? The example of #VaginalCancer on Instagram
Int J Gynecol Cancer, 33 (9), 1488-1489
DOI 10.1136/ijgc-2023-004844, PubMed 37591610 -
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Cancers (Basel), 15 (6)
DOI 10.3390/cancers15061823, PubMed 36980708 -
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Clin Cancer Res, 29 (9), 1698-1707
DOI 10.1158/1078-0432.CCR-22-2032, PubMed 36595569 -
Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients
Int J Gynecol Cancer, 33 (8), 1287-1294
DOI 10.1136/ijgc-2023-004356, PubMed 37451689 -
Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
Int J Gynecol Cancer, 33 (8), 1279-1286
DOI 10.1136/ijgc-2023-004355, PubMed 37451690 -
Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden - a population-based study
Acta Obstet Gynecol Scand, 103 (4), 669-683
DOI 10.1111/aogs.14677, PubMed 37694965 -
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
N Engl J Med, 388 (23), 2145-2158
DOI 10.1056/NEJMoa2216334, PubMed 36972026 -
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Lancet, 403 (10421), 31-43
DOI 10.1016/S0140-6736(23)02405-4, PubMed 38048793 -
Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study
Gynecol Oncol, 179, 52-62
DOI 10.1016/j.ygyno.2023.10.012, PubMed 37924595 -
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Ann Oncol, 34 (12), 1152-1164
DOI 10.1016/j.annonc.2023.09.3110, PubMed 37797734 -
Self-reported distress and problems after treatment for gynecological cancer - Correlation between a short screening tool and longer measures of anxiety/depression and health-related quality of life
Acta Obstet Gynecol Scand, 103 (2), 387-395
DOI 10.1111/aogs.14709, PubMed 37991142 -
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis
Eur J Surg Oncol, 49 (9), 106958
DOI 10.1016/j.ejso.2023.06.010, PubMed 37349160 -
Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
Int J Gynecol Cancer, 33 (12), 1898-1905
DOI 10.1136/ijgc-2023-004484, PubMed 38000795
Publications 2022
-
Circulating metabolites in the early stage of breast cancer were not related to cancer stage or subtypes but associated with ki67 level. Promising statistical discrimination from controls
Mol Cell Probes, 66, 101862
DOI 10.1016/j.mcp.2022.101862, PubMed 36162596 -
Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
Cancers (Basel), 14 (14)
DOI 10.3390/cancers14143536, PubMed 35884597 -
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
Cytopathology, 33 (4), 479-492
DOI 10.1111/cyt.13126, PubMed 35398934 -
Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)
Acta Oncol, 61 (8), 939-945
DOI 10.1080/0284186X.2022.2088249, PubMed 35762031 -
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
Virchows Arch, 480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717 -
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study
Gynecol Oncol, 167 (3), 452-457
DOI 10.1016/j.ygyno.2022.09.025, PubMed 36243601 -
Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2022-003361, PubMed 35680138 -
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
Cancer, 128 (16), 3080-3089
DOI 10.1002/cncr.34350, PubMed 35714310 -
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630 -
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecol Oncol, 166 (1), 36-43
DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709 -
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
Int J Gynecol Cancer, 32 (2), 181-188
DOI 10.1136/ijgc-2021-002898, PubMed 34987096 -
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
J Clin Oncol, 41 (4), 893-902
DOI 10.1200/JCO.22.01010, PubMed 36332161 -
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Gynecol Oncol, 164 (3), 498-504
DOI 10.1016/j.ygyno.2021.12.025, PubMed 35063276 -
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
Gynecol Oncol, 165 (2), 230-238
DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281 -
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
Radiother Oncol, 176, 17-24
DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778 -
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529 -
Changes in Subjective Measures of Cognitive Function in Older Adults From the Initiation Through 12 Months After the Receipt of Chemotherapy
Cancer Nurs, 46 (6), E365-E374
DOI 10.1097/NCC.0000000000001140, PubMed 35781267
Publications 2021
-
Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study
Psychooncology, 31 (2), 298-305
DOI 10.1002/pon.5818, PubMed 34516040 -
International Gynaecological Cancer Society (IGCS) 2020 Annual Global Meeting: Twitter activity analysis
Int J Gynecol Cancer, 31 (11), 1453-1458
DOI 10.1136/ijgc-2021-002781, PubMed 34489352 -
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
Virchows Arch, 479 (2), 419-424
DOI 10.1007/s00428-021-03057-x, PubMed 33595736 -
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
J Clin Med, 10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260 -
Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique
Curr Opin Oncol, 33 (5), 457-463
DOI 10.1097/CCO.0000000000000777, PubMed 34264897 -
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
Sci Rep, 11 (1), 23463
DOI 10.1038/s41598-021-02820-z, PubMed 34873230 -
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
Biomarkers, 26 (4), 302-308
DOI 10.1080/1354750X.2021.1891291, PubMed 33645339 -
The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
Acta Oncol, 60 (4), 434-443
DOI 10.1080/0284186X.2021.1891281, PubMed 33651647 -
Association of patient-reported outcomes and ovarian cancer recurrence
Int J Gynecol Cancer, 31 (9), 1248-1259
DOI 10.1136/ijgc-2021-002550, PubMed 34489355 -
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
Cancers (Basel), 13 (22)
DOI 10.3390/cancers13225848, PubMed 34831000 -
Association of Circulating miRNA Expression with Preeclampsia, Its Onset, and Severity
Diagnostics (Basel), 11 (3)
DOI 10.3390/diagnostics11030476, PubMed 33800458 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 31 1, 20 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 31 2, 18 -
Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
Cancers (Basel), 13 (6)
DOI 10.3390/cancers13061367, PubMed 33803531 -
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
J Clin Oncol, 39 (32), 3623-3632
DOI 10.1200/JCO.21.00006, PubMed 34432481 -
Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer
Acta Obstet Gynecol Scand, 101 (3), 313-322
DOI 10.1111/aogs.14310, PubMed 34964982 -
Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report
Eur J Cancer, 148, 124-133
DOI 10.1016/j.ejca.2021.02.022, PubMed 33743481 -
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
Gynecol Oncol, 162 (2), 284-291
DOI 10.1016/j.ygyno.2021.05.028, PubMed 34083029 -
Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study
Int J Gynecol Cancer, 31 (8), 1106-1115
DOI 10.1136/ijgc-2020-002377, PubMed 33858949 -
Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy
Nurs Open, 9 (2), 1040-1051
DOI 10.1002/nop2.1141, PubMed 34878233 -
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
Am J Obstet Gynecol, 225 (4), 407.e1-407.e16
DOI 10.1016/j.ajog.2021.05.007, PubMed 34019887 -
Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking
BMJ Open, 11 (7), e050930
DOI 10.1136/bmjopen-2021-050930, PubMed 34253678
Publications 2020
-
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139 -
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Int J Gynecol Cancer, 30 (12), 1997-2001
DOI 10.1136/ijgc-2020-001572, PubMed 32606097 -
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004 -
Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study
Int J Mol Sci, 21 (19)
DOI 10.3390/ijms21197288, PubMed 33023154 -
Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
Int J Gynecol Cancer, 30 (9), 1444-1449
DOI 10.1136/ijgc-2020-001528, PubMed 32586892 -
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123838, PubMed 33352679 -
Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
EPMA J, 11 (2), 261-287
DOI 10.1007/s13167-020-00210-5, PubMed 32547652 -
Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
BMJ Support Palliat Care (in press)
DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506 -
Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists
Int J Gynecol Cancer, 31 (4), 575-584
DOI 10.1136/ijgc-2020-002176, PubMed 33361458 -
Systematic treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 30 1, 15 -
Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
Acta Oncol, 59 (6), 636-643
DOI 10.1080/0284186X.2020.1744717, PubMed 32238040 -
DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
Radiat Oncol, 15 (1), 79
DOI 10.1186/s13014-020-01526-2, PubMed 32293487 -
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Gynecol Oncol, 159 (2), 442-448
DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695 -
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
J Clin Oncol, 38 (32), 3753-3762
DOI 10.1200/JCO.20.01164, PubMed 32822286 -
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
Int J Gynecol Cancer, 30 (11), 1748-1756
DOI 10.1136/ijgc-2020-001403, PubMed 32784203 -
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
JAMA Netw Open, 3 (1), e1918939
DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558 -
COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
Int J Gynecol Cancer, 30 (5), 561-563
DOI 10.1136/ijgc-2020-001419, PubMed 32221023 -
International Gynecologic Cancer Society 2019 meeting summary
Int J Gynecol Cancer, 30 (2), 167-173
DOI 10.1136/ijgc-2019-001146, PubMed 32029483 -
Base rate of ovarian cancer on algorithms in patients with a pelvic mass
Int J Gynecol Cancer, 30 (11), 1775-1779
DOI 10.1136/ijgc-2020-001416, PubMed 32699016 -
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
J Appl Lab Med, 5 (2), 263-272
DOI 10.1093/jalm/jfz012, PubMed 32445385 -
The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis
J Cancer Res Clin Oncol, 146 (12), 3137-3154
DOI 10.1007/s00432-020-03424-2, PubMed 33063131 -
Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
EPMA J, 11 (3), 377-398
DOI 10.1007/s13167-020-00217-y, PubMed 32843908 -
Fifteen Years’ Experience with Vulvar Verrucous Carcinoma at a Single Norwegian Academic Cancer Center
Journal of Gynecology and Women Healthcare, 2 (2), 1-4
PublikaID 489 -
Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer
Clin Breast Cancer, 20 (6), e711-e722
DOI 10.1016/j.clbc.2020.05.009, PubMed 32792225 -
Preferences for follow up in long-term survivors after cervical cancer
Acta Obstet Gynecol Scand, 99 (9), 1253-1259
DOI 10.1111/aogs.13855, PubMed 32232835 -
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
Cancers (Basel), 12 (5)
DOI 10.3390/cancers12051292, PubMed 32443784 -
Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
Int J Mol Sci, 21 (21)
DOI 10.3390/ijms21217988, PubMed 33121141
Publications 2019
-
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
Clin Cancer Res, 25 (7), 2155-2165
DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134 -
Endometrial cancer during pregnancy: management strategies
Int J Gynecol Cancer, 29 (7), 1221-1224
DOI 10.1136/ijgc-2019-000756, PubMed 31434687 -
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Gynecol Oncol, 152 (3), 560-567
DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768 -
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
Neoplasia, 21 (4), 353-362
DOI 10.1016/j.neo.2019.01.002, PubMed 30856376 -
Summary of landmark papers published between August 2018 and May 2019
Int. J. Gynecol. Cancer, 29 1, 1-5
DOI 10.1136/ijgc-2019-000738 -
Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
Acta Oncol, 58 (6), 828-837
DOI 10.1080/0284186X.2019.1580386, PubMed 30810443 -
Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
Transl Oncol, 12 (3), 576-584
DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934 -
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
Int J Gynecol Cancer, 29 (1), 181-187
DOI 10.1136/ijgc-2018-000021, PubMed 30640702 -
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Cochrane Database Syst Rev, 10 (10), CD012160
DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998
Publications 2018
-
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
Gynecol Oncol, 152 (1), 53-60
DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719 -
Chromatin organisation and cancer prognosis: a pan-cancer study
Lancet Oncol, 19 (3), 356-369
DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 28 4, 29 -
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Cancer Chemother Pharmacol, 83 (1), 97-105
DOI 10.1007/s00280-018-3706-5, PubMed 30368585 -
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
Gynecol Oncol, 150 (2), 239-246
DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697 -
PREFACE
Int. J. Gynecol. Cancer, 28 4, 2 -
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712 -
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
J Natl Cancer Inst, 110 (12), 1400-1408
DOI 10.1093/jnci/djy063, PubMed 29684152 -
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
Acta Oncol, 57 (8), 1100-1108
DOI 10.1080/0284186X.2018.1440085, PubMed 29451070 -
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790 -
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455 -
Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
Acta Obstet Gynecol Scand, 98 (2), 240-249
DOI 10.1111/aogs.13477, PubMed 30289161 -
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
DOI 10.1111/aogs.13361, PubMed 29790149
Publications 2017
-
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905 -
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Virchows Arch, 471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014 -
A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
Int J Gynecol Cancer, 27 (4), 743-747
DOI 10.1097/IGC.0000000000000959, PubMed 28375931 -
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999 -
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432 -
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Am J Surg Pathol, 41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181 -
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
Acta Obstet Gynecol Scand, 96 (5), 547-555
DOI 10.1111/aogs.13120, PubMed 28236297 -
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630 -
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323 -
Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
Int J Gynecol Cancer, 27 (6), 1274-1282
DOI 10.1097/IGC.0000000000000981, PubMed 28498237 -
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
Int J Gynecol Cancer, 27 (5), 1046-1050
DOI 10.1097/IGC.0000000000000982, PubMed 28525497 -
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
Acta Oncol, 56 (5), 675-681
DOI 10.1080/0284186X.2017.1294762, PubMed 28447564 -
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
Gynecol Oncol, 145 (3), 543-548
DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187 -
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Ann Surg Oncol, 24 (9), 2720-2726
DOI 10.1245/s10434-017-5919-y, PubMed 28608122 -
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
Eur J Surg Oncol, 45 (1), 67-74
DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961 -
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
Gynecol Oncol, 145 (1), 148-153
DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195 -
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395 -
A study of chronic fatigue in Norwegian cervical cancer survivors
Gynecol Oncol, 146 (3), 630-635
DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254 -
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
Acta Obstet Gynecol Scand, 96 (10), 1162-1169
DOI 10.1111/aogs.13199, PubMed 28795770 -
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol, 19 (7), 976-985
DOI 10.1093/neuonc/now272, PubMed 28040713 -
Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
Acta Oncol, 56 (10), 1302-1309
DOI 10.1080/0284186X.2017.1330554, PubMed 28548875 -
A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
Int J Gynecol Cancer, 27 (3), 620-626
DOI 10.1097/IGC.0000000000000917, PubMed 28187096
Publications 2016
-
Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
Obstet Gynecol, 128 (6), 1265-1273
DOI 10.1097/AOG.0000000000001777, PubMed 27824756 -
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
Am J Clin Pathol, 145 (4), 449-58
DOI 10.1093/ajcp/aqw030, PubMed 27149024 -
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Clin Cancer Res, 22 (16), 4067-76
DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812 -
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
PLoS One, 11 (5), e0156259
DOI 10.1371/journal.pone.0156259, PubMed 27244197 -
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
DOI 10.1007/s13277-016-4940-2, PubMed 26867771 -
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Gynecol Oncol, 142 (3), 458-64
DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035 -
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Gynecol Oncol, 140 (3), 457-62
DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488 -
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
PLoS One, 11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508 -
Medical treatment of primary or recurrent cervical cancer
Int. J. Gynecol. Cancer, 26 1, 42-43 -
Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
Int. J. Gynecol. Cancer, 26 1, 5-8 -
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
DOI 10.1093/annonc/mdw238, PubMed 27407100 -
Preface
Int. J. Gynecol. Cancer, 26 1, 2 -
Life - Literature for ENYGO
Int. J. Gynecol. Cancer, 26 4, 2-73 -
Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
BMJ Open, 6 (11), e013728
DOI 10.1136/bmjopen-2016-013728, PubMed 28186949 -
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
Oncologist, 21 (6), 745-54
DOI 10.1634/theoncologist.2015-0239, PubMed 27009938 -
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
N Engl J Med, 375 (22), 2154-2164
DOI 10.1056/NEJMoa1611310, PubMed 27717299 -
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471 -
Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
Eur J Surg Oncol, 42 (4), 513-22
DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445 -
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577 -
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723 -
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
DOI 10.12892/ejgo3007.2016, PubMed 27352555 -
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
Oncotarget, 7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585 -
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
Ann Oncol, 27 (9), 1733-9
DOI 10.1093/annonc/mdw236, PubMed 27287207 -
Medical treatment of primary ovarian cancer
Int. J. Gynecol. Cancer, 26 1, 9-11 -
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Br J Cancer, 115 (2), 228-35
DOI 10.1038/bjc.2016.194, PubMed 27351218
Publications 2015
-
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
PLoS One, 10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914 -
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
DOI 10.1007/s10689-015-9811-2, PubMed 25980896 -
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230 -
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol, 17 (1), 78-89
DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673 -
MicroRNAs in Ovarian Cancer
Hum Pathol, 46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350 -
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
Epigenetics, 10 (10), 970-80
DOI 10.1080/15592294.2015.1085140, PubMed 26291246 -
Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
Gynecol Oncol, 139 (3), 476-80
DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365 -
The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
ESC Heart Fail, 2 (3), 142-149
DOI 10.1002/ehf2.12048, PubMed 28834675 -
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338 -
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687 -
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Lancet Oncol, 16 (8), 928-36
DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797 -
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Eur J Cancer, 51 (7), 825-32
DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433 -
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Genome Med, 7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652 -
Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
Eur J Epidemiol, 31 (1), 95-8
DOI 10.1007/s10654-015-0033-6, PubMed 25903163
Publications 2014
-
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
DOI 10.1097/IGC.0000000000000205, PubMed 25033257 -
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994 -
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216 -
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803 -
Ovarian cancer: diagnostic, biological and prognostic aspects
Womens Health (Lond), 10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543 -
The clinical and diagnostic role of microRNAs in ovarian carcinoma
Gynecol Oncol, 133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546 -
The role of the tumor stroma in ovarian cancer
Front Oncol, 4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785 -
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501 -
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303 -
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
DOI 10.1186/1471-2407-14-68, PubMed 24498853 -
Genomic profile of ovarian carcinomas
BMC Cancer, 14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194 -
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
PLoS Biol, 12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521 -
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
Cytometry A, 87 (4), 315-25
DOI 10.1002/cyto.a.22601, PubMed 25483227 -
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290 -
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323 -
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
Eur J Cancer, 50 (11), 1942-50
DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045 -
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159 -
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085 -
Exosome-derived miRNAs and ovarian carcinoma progression
Carcinogenesis, 35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027 -
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
BMC Cancer, 14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620 -
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937
DOI 10.1186/1471-2407-14-937, PubMed 25494701
Publications 2013
-
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
Radiother Oncol, 107 (1), 117-22
DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024 -
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714 -
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
Hum Pathol, 45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798 -
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953 -
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
Gynecol Oncol, 131 (2), 437-44
DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107 -
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
J Pathol, 230 (1), 59-69
DOI 10.1002/path.4168, PubMed 23335387 -
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
DOI 10.1200/JCO.2013.48.8023, PubMed 24019546 -
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518 -
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671 -
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum Pathol, 44 (12), 2677-83
DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004 -
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Publications 2012
-
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
DOI 10.1186/1471-2407-12-454, PubMed 23039163 -
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560 -
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
Gynecol Oncol, 128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314 -
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Gynecol Oncol, 128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104 -
ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
PLoS One, 7 (9), e46317
DOI 10.1371/journal.pone.0046317, PubMed 23029477 -
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
Acta Obstet Gynecol Scand, 91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605 -
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
Ann Surg Oncol, 20 (4), 1348-54
DOI 10.1245/s10434-012-2673-z, PubMed 23054114 -
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Clin Cancer Res, 18 (11), 3197-206
DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981 -
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
Cancer Res, 72 (20), 5285-95
DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239 -
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403 -
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409 -
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154 -
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921 -
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637 -
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
DOI 10.1371/journal.pone.0036263, PubMed 22558411 -
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
Ann Oncol, 24 (4), 937-43
DOI 10.1093/annonc/mds538, PubMed 23104722 -
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
BMC Cancer, 12, 201
DOI 10.1186/1471-2407-12-201, PubMed 22642602 -
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-2619
DOI 10.1093/annonc/mds060, PubMed 22539562 -
Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
Gynecol Obstet Invest, 75 (1), 61-7
DOI 10.1159/000345072, PubMed 23220872 -
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
Anal Cell Pathol (Amst), 35 (4), 305-14
DOI 10.3233/ACP-2012-0065, PubMed 22596183 -
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999 -
Diagnosis and treatment of sarcoma of the uterus. A review
Acta Oncol, 51 (6), 694-705
DOI 10.3109/0284186X.2012.689111, PubMed 22793037 -
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Eur J Cancer, 48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201 -
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906 -
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351 -
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer, 107 (4), 588-91
DOI 10.1038/bjc.2012.307, PubMed 22836511 -
Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
Int J Mol Sci, 13 (10), 12925-38
DOI 10.3390/ijms131012925, PubMed 23202930
Publications 2011
-
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
Int J Radiat Oncol Biol Phys, 82 (3), e485-92
DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954 -
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
Cancer Chemother Pharmacol, 69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668 -
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113 -
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Tumour Biol, 32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924 -
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111 -
"The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
Qual Life Res, 21 (8), 1459-70
DOI 10.1007/s11136-011-0053-y, PubMed 22045155 -
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
Hum Pathol, 42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424 -
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542 -
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
Hum Pathol, 43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883 -
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
Mol Pharm, 8 (6), 2080-8
DOI 10.1021/mp200240a, PubMed 21761824 -
Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
Int J Gynecol Cancer, 21 (8), 1500-6
DOI 10.1097/IGC.0b013e3182202d17, PubMed 21720256 -
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
Radiother Oncol, 101 (1), 152-7
DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035 -
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
Clin Cancer Res, 17 (16), 5501-12
DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508 -
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408 -
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
Mol Oncol, 6 (1), 98-107
DOI 10.1016/j.molonc.2011.10.002, PubMed 22062770 -
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-53
DOI 10.1002/cncr.26449, PubMed 22009736 -
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605 -
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
Ann Oncol, 22 (11), 2417-2423
DOI 10.1093/annonc/mdr001, PubMed 21402619 -
The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
Eur J Gynaecol Oncol, 32 (4), 369-76
PubMed 21941955 -
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701 -
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol, 23 (5), 1178-1184
DOI 10.1093/annonc/mdr368, PubMed 21965471 -
Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
Gynecol Oncol, 121 (3), 600-4
DOI 10.1016/j.ygyno.2011.02.002, PubMed 21353294 -
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
Ann Surg Oncol, 19 (2), 597-604
DOI 10.1245/s10434-011-1873-2, PubMed 21732142 -
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115 -
Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
J Clin Oncol, 29 (31), 4076-8
DOI 10.1200/JCO.2011.36.9785, PubMed 21931032 -
A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
J Cancer Surviv, 5 (2), 208-16
DOI 10.1007/s11764-011-0172-z, PubMed 21259075 -
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Br J Cancer, 105 (7), 890-6
DOI 10.1038/bjc.2011.328, PubMed 21878937
Publications 2010
-
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
Int J Gynecol Cancer, 20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029 -
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Hum Pathol, 41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512 -
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol Histopathol, 25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439 -
Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
J. Clin. Oncol., 28 (27), 4162-4169
DOI 10.1200/JCO.2009.27.4696 -
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
PLoS One, 5 (11), e13837
DOI 10.1371/journal.pone.0013837, PubMed 21079801 -
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin Exp Metastasis, 27 (3), 161-72
DOI 10.1007/s10585-010-9315-2, PubMed 20213325 -
A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
Br J Cancer, 102 (6), 957-65
DOI 10.1038/sj.bjc.6605594, PubMed 20197765 -
Genomic aberrations in borderline ovarian tumors
J Transl Med, 8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781 -
Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
Genes Chromosomes Cancer, 49 (11), 1046-53
DOI 10.1002/gcc.20813, PubMed 20725991 -
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
Int J Gynecol Cancer, 20 (2), 233-9
DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665 -
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
Am J Pathol, 177 (3), 1087-94
DOI 10.2353/ajpath.2010.100316, PubMed 20671266 -
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
Int J Gynecol Pathol, 29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853 -
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
BMC Cancer, 10, 493
DOI 10.1186/1471-2407-10-493, PubMed 20843305 -
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
J. Clin. Oncol., 28 (20), 3323-3329
DOI 10.1200/JCO.2009.25.7519 -
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Lancet, 376 (9747), 1155-63
DOI 10.1016/S0140-6736(10)61268-8, PubMed 20888993 -
Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
Int J Med Robot, 6 (2), 132-5
DOI 10.1002/rcs.295, PubMed 20049750 -
Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
Gynecol Oncol, 117 (2), 389; author reply 389-90
DOI 10.1016/j.ygyno.2010.01.032, PubMed 20153028 -
Management of cervical carcinoma stage IV: comment.
CME Journal of Gynecologic Oncology, 15 (1), 69-71
PublikaID 105 -
Surgery in treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 33-39
PublikaID 104 -
The treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 72-90
PublikaID 106 -
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
N Engl J Med, 363 (10), 943-53
DOI 10.1056/NEJMoa0908806, PubMed 20818904 -
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813 -
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
Diagn Cytopathol, 39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893